Description: In the latest trading session, Amgen (AMGN) closed at $328.97, marking a +1.44% move from the previous day.

Description: Honeywell said its‌ quantum computing unit Quantinuum will file for an IPO, adding to the growing number of quantum computing stocks.

Description: Key Insights Using the 2 Stage Free Cash Flow to Equity, Amgen fair value estimate is US$637 Current share price of...

Description: [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global T-Cell Engagers Market size & share revenue was valued at approximately USD 2.4 Billion in 2024 and is expected to reach USD 2.5 Billion in 2025 and is expected to reach around USD 18.8 Billion by 2034, at a CAGR of 21.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen, Genmab, Roche/Genentech, Ma

Description: Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Description: Ro, the leading direct-to-patient healthcare company, today announced a research collaboration with Amgen to study barriers to care and patients' treatment experience. Powered by data from Ro's nationwide platform, the research will evaluate the real-world challenges that patients and providers must navigate in order to access and deliver evidence-based obesity care.

Description: Amgen (NASDAQ:AMGN) Chief Executive Officer Bob Bradway told attendees at a J.P. Morgan-hosted event that the company views 2026 as a “springboard year,” driven in part by what he described as a significant amount of clinical data expected across the portfolio. Bradway also reviewed 2025 performance

Description: Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Description: If you are wondering whether Amgen's current share price still offers value after a strong run, this article walks through what the numbers are really saying about the stock. Over the last year Amgen has returned 28.4%, with a 3.4% gain over the past 30 days, while the year-to-date return and 7-day move both sit at 0.5% declines, which may have shifted how some investors think about its potential and risk. Recent headlines around Amgen have focused on its position as a large biotech player,...

Description: JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.

Description: These five Dogs of the Dow may be the perfect play for 2026 for growth and income investors wary of volatility and a potential sell-off.

Description: The New Jersey pharma will now offer some of its branded medicines on the US government-created DTC platform, TrumpRx.gov.

Description: In the closing of the recent trading day, Amgen (AMGN) stood at $330.05, denoting a -3.39% move from the preceding trading day.

Description: The hefty funding will fuel Phase 2 testing of a drug with a similar mechanism to Amgen’s closely watched obesity drug, as well as an amylin-targeting weight loss medicine.

Description: In early January 2026, DISCO Pharmaceuticals announced it had granted Amgen exclusive global rights to develop and commercialize cancer therapies based on a cell-surface target identified by DISCO’s proteomics and protein community mapping platform, with DISCO eligible for up to US$618 million in potential payments plus royalties. The deal gives Amgen access to a differentiated surfaceome-targeting engine that can inform bispecific antibody-drug conjugates and T‑cell engagers, potentially...

Description: There is an even more important question to address.

Description: The Dow Jones index dipped in mixed trade Wednesday after surprise jobs data. Bitcoin stock Strategy jumped.

Description: US equity indexes closed mixed on Wednesday, with the S&P 500 and the Dow Jones Industrial Average r

Description: Amgen (NASDAQ:AMGN) will present at the 2026 J.P. Morgan Healthcare Conference at 3:45 p.m. PT on Monday, January 12, 2026. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

Description: Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.

Description: According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology pipeline.

Description: Collaboration with Amgen to advance a cancer target discovered using DISCO’s proprietary surfaceome mapping technology Cologne, Germany, January 7, 2026 – DISCO Pharmaceuticals (“DISCO”), today announced an exclusive license agreement with Amgen to advance novel therapeutic candidates addressing a target that was mapped on the surface of a cancer cell by DISCO’s proprietary platform. Under the terms of the agreement, DISCO will be eligible to receive up to $618 million total potential deal value

Description: The acquisition adds a preclinical protein degrader program targeting acute myeloid leukemia to Amgen's oncology pipeline.

Description: Dark Blue Therapeutics ("Dark Blue"), a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen (NASDAQ: AMGN).

Description: Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to $840 million.

Description: Amgen will release its fourth-quarter earnings soon, and analysts anticipate a low double-digit profit dip.

Description: While obexelimab failed to best Uplizna in terms of efficacy, Zenas will still file for the drug’s approval in IgG4-RD.

Description: The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that could set it apart from current medications.

Description: In the closing of the recent trading day, Amgen (AMGN) stood at $320.71, denoting a -2.12% move from the preceding trading day.

Description: Stock Market Today: The Dow Jones index rose after the U.S. ousted Venezuelan President Maduro. Nvidia rallied and Reddit tested an entry.

Description: Zenas BioPharma stock collapsed Monday despite technically succeeding in a Phase 3 study of its treatment for a rare autoimmune disorder.

Description: Zenas BioPharma (ZBIO) reported Monday that a phase 3 trial of obexelimab in immunoglobulin G4-relat

Description: What Changed in the Amgen Story Amgen’s fair value estimate has been adjusted slightly, moving from about US$322.88 per share to roughly US$327.74 per share, with the discount rate and revenue growth assumptions shifting only modestly. This updated view reflects how mixed Street research is being balanced between confidence in Amgen as a core large cap biopharma name and questions around long term earnings visibility as key products approach patent expiry. Stay with this article to see how...

Description: LTM, GM and AMGN highlight Zacks' recent stock-picking wins, delivering notable gains across airlines, autos and biotech despite choppy markets.

Description: While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear to match the effectiveness of a recently approved Amgen drug.

Description: Amgen (AMGN) has been quietly grinding higher over the past year, and that steady move is catching more investor attention. With revenue and earnings both growing, the stock’s recent pullback looks worth a closer look. See our latest analysis for Amgen. At around $327.64, Amgen’s modest recent share price pullback comes after a strong 90 day share price return of 11.4 percent and a one year total shareholder return of 29.5 percent, which suggests momentum is still broadly constructive. If...

Description: Axsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Description: High-yielding Dow stocks outperformed the broader market this year. Will new Dow dogs Home Depot, Nike, and UnitedHealth keep the streak going?

Description: Amgen Inc. (NASDAQ:AMGN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. Amgen Inc. (NASDAQ:AMGN) has outperformed the broader market this year, supported by strong financial results and steady clinical progress, even as investors keep an eye on upcoming patent expirations. The stock is up more than 27% since the start […]

Description: AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.

Description: AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo Nordisk push oral GLP-1s.

Description: High-yielding Dow stocks outperformed the broader market this year. Will new Dow dogs Home Depot, Nike, and UnitedHealth keep the streak going?

Description: Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: AMGN signs a pricing deal with the Trump administration, cutting U.S. drug costs, expanding DTC access and securing tariff relief tied to domestic investment.

Description: One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Description: NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison.

Description: The latest trading day saw Amgen (AMGN) settling at $331.39, representing a +1.22% change from its previous close.

Description: Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.

Description: Wondering if Amgen at around $327 a share is still worth buying, or if the easy money has already been made? You are not alone. Let us break down whether the current price really matches the business underneath. The stock is up 3.0% over the last week and 26.3% year to date, even after a 4.4% dip over the past month, leaving it roughly 28.3% higher than a year ago and 71.9% over five years. That kind of run naturally raises the question of whether investors are now paying too much for future...

Description: Dow Jones stock Merck and eight other bellwether pharma companies struck drug-pricing agreements with the Trump administration on Friday.

Description: President Trump announced deals with nine major drug makers in a move to reduce pharmaceutical prices, granting a three-year break on trade tariffs if they invest more into US manufacturing. Market Domination Overtime host Jared Blikre breaks down the news. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad. “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office.

Description: The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.

Description: Health care stocks rose late Friday afternoon, with the NYSE Health Care Index increasing 0.8% and t

Description: Nine pharmaceutical companies including Merck and GSK agreed to lower certain U.S. prices for their medicines in a new round of industry pacts with the Trump administration. The companies agreed to reduce U.S. prices on drugs to levels comparable with prices charged in other wealthy countries, which are generally much lower. Merck, for example, said it would make diabetes drugs Januvia and Janumet available to eligible American patients at a cash price that is 70% off the current list price through a direct-to-patient program.

Description: Amgen (NASDAQ:AMGN) today announced it is taking action again with the U.S. government to lower medicine costs for American patients, while reinforcing Amgen's long-standing commitment to innovation. The action satisfies the components outlined in President Trump's July 31 letter, including the Administration's Most Favored Nation pricing requests. Additional details remain confidential.

Description: The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to challenge Bristol Myers Squibb’s Sotyktu.

Description: Amgen (AMGN) just picked up a meaningful FDA win, with UPLIZNA cleared for a specific subset of adults with generalized myasthenia gravis, expanding both the drug’s addressable market and the company’s autoimmune footprint. See our latest analysis for Amgen. The UPLIZNA approval lands at a time when momentum in Amgen’s stock is quietly building, with the recent autoimmune wins, orphan drug progress and a dividend hike helping underpin an 18.94% 3 month share price return and a 5 year total...

Description: Amgen Inc. (NASDAQ:AMGN) is included among the 12 Best Dogs of the Dow to Invest in. On December 8, HSBC lifted its price target on Amgen Inc. (NASDAQ:AMGN) to $425 from $381. The firm also retained a Buy rating. The call came as part of the firm’s 2026 outlook for the pharma sector. HSBC sees […]

Description: Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best Blue-Chip Stocks with Growing Dividends. On December 12, Morgan Stanley cut its price target for Amgen Inc. (NASDAQ:AMGN) from $329 to $304, but kept its Equal Weight rating. The firm’s 2026 biopharma outlook sounds more optimistic, noting that a lot of the policy headaches that dragged […]

Description: Earlier this month, Amgen announced that the FDA approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-AChR and anti-MuSK antibody positive, making it the first and only CD19-targeted B-cell therapy for this condition with maintenance dosing just twice a year after loading. This latest indication, added to UPLIZNA’s existing approvals in neuromyelitis optica spectrum disorder and IgG4-related disease, further reinforces Amgen’s position in rare, B...

Description: The latest trading day saw Amgen (AMGN) settling at $325.31, representing a +2.38% change from its previous close.

Description: Stock Market Today: The Dow fell Monday. President Trump edged closer to a Fed chair pick. Progress was made in Ukraine peace talks. Some stocks tested buy points.

Description: These dividend growth machines could have considerable upside for long-term investors.

Description: Amgen Inc. ( NASDAQ:AMGN ) will increase its dividend from last year's comparable payment on the 6th of March to $2.52...

Description: AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market.

Description: Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) and anti-muscle specific tyrosine kinase (MuSK) antibody positive. The approval offers patients a new targeted treatment option that has the potential for long-term disease control with just two doses a year, after two initial loading doses.

Description: In the last year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a substantial stake in the company which may have...

Description: The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Description: Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the first quarter of 2026. The dividend will be paid on March 6, 2026, to all stockholders of record as of the close of business on February 13, 2026.

Description: The stock market was struggling to hold onto even modest gains on Tuesday. The Dow was down 111 points, or 0.2%. The S&P 500 was up just 0.1%. The Nasdaq Composite was up 0.2%. Though a slim majority of stocks in the S&P 500 were up on the day, market breadth was slipping.

Description: The city’s Goldilocks status as an employer magnet with still-reasonable housing is now on shaky ground.

Description: The global Merkel Cell Carcinoma (MCC) market is rapidly evolving, driven by advancements in immunotherapy and a surge in early diagnoses. Merkel cell carcinoma, a rare, aggressive skin cancer mainly affecting older adults, is increasingly being treated with immune checkpoint inhibitors like Keytruda and Opdivo, which have revolutionized patient survival rates. The market faces challenges with the high cost of treatments impacting accessibility. Key players such as Merck, Bristol Myers Squibb, a

Description: J&J faces Stelara losses, Medicare shifts, talc suits and China pressure, banking on new products and expects segment growth to stay on track.

Description: Inductive Bio, an AI drug discovery partner developing virtual chemistry labs, announced today that it has received an up to $21M award to lead a project to develop next-generation models of drug toxicity to advance safer therapeutics and reduce reliance on animal testing. The company has teamed up with Amgen, Cincinnati Children's Hospital Medical Center, Baylor College of Medicine, and Torch Bio, a University of Michigan Medical School spinout company, to use AI trained on data from advanced h

Description: Key Insights Amgen's estimated fair value is US$554 based on 2 Stage Free Cash Flow to Equity Amgen's US$330 share...

Description: Amgen Inc. (NASDAQ:AMGN) is included among the 15 Blue Chip Dividend Stocks to Build a Passive Income Porfolio. On December 3, BMO Capital’s Evan Seigerman increased the firm’s price target on Amgen Inc. (NASDAQ:AMGN) to $372 from $335 and reiterated an Outperform rating. The analyst noted that the data from the Maritide Phase 2 Part […]

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally. Cramer mentioned the stock during the episode, as he commented: “Then it might be a comeback to the drug stocks. Why? Well, remember, lots of people think the economy is stalled or in a tailspin. They’re […]

Description: Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: The Los Angeles Sports & Entertainment Commission (LASEC), which serves as the lead for the Los Angeles World Cup 2026 Host Committee, today announced that Amgen, a leading biotechnology company headquartered in Greater Los Angeles, has been named a Foundational Partner and the Official Biotech Partner of LASEC. Amgen will also become an Official Los Angeles World Cup 2026 Host City Supporter.

Description: Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.

Description: Amgen Inc. (NASDAQ:AMGN) ranks among the Best Low Volatility Investments in December 2025. Goldman Sachs reaffirmed its $400 price target and Buy rating for Amgen Inc. (NASDAQ:AMGN) on November 25 ahead of two Phase 2 updates for the company’s obesity medication MariTide, which are anticipated by year’s end. Following previously disclosed induction results from Part […]

Description: MILLBRAE, Calif., December 02, 2025--Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with cutting-edge research to accelerate drug discovery, today announced the election of David W. Meline as an independent director effective November 23, 2025. Mr. Meline is the former Chief Financial Officer at Moderna Inc.

Description: Amgen (AMGN) just received full approval from the FDA for IMDELLTRA in treating adult patients with extensive stage small cell lung cancer after platinum-based chemotherapy. The NCCN also updated guidelines and named IMDELLTRA the only Category 1 preferred therapy in this scenario. See our latest analysis for Amgen. Amgen’s momentum has picked up meaningfully this year, with its recent FDA approval for IMDELLTRA building on earlier upbeat news such as robust Q3 earnings and a strong lineup of...

Description: Amgen’s stock narrative is shifting, as reflected in a slight but noticeable increase in the consensus analyst price target from $318.51 to $322.88. This modest revision comes amid a backdrop of mixed analyst sentiment, with optimism regarding Amgen’s innovative pipeline and stable revenue base being balanced against concerns over patent expiries and the pace of new product adoption. For those closely following Amgen, understanding these updates is key. Keep reading to learn how to track...

Description: Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to Prolia® (Amgen), and Jubereq (denosumab), a biosimilar to Xgeva® (Amgen), following the scheduled expiry of the reference medicine's patent on 27 November 2025.

Description: The Dow fell on the stock market today. Moderna skidded after an FDA memo linked Covid vaccines to deaths. A gold stock cleared an entry.

Description: Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.

Description: By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Multiple Data Readouts Ahead in 2026 Following the recent approval of REDEMPLO ® for the treatment of patients with familial chylomicronemia syndrome (FCS), Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is now a commercial-stage company and recently reported that the drug is available for patients only one week

Description: Curious if Amgen is worth your investment dollars right now? Let’s take a clear-eyed look at where the stock stands and whether the value justifies the price. Amgen's stock has been on a strong upward path lately, gaining 2.3% in the past week and 18.3% over the last month. This has fueled conversations about its ongoing growth story. Recent headlines highlight Amgen's progress in the biotech space, including promising results from clinical trials and new drug approvals that have piqued...

Description: Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer discussed, along with the need for diversification. Cramer highlighted that he is fond of the stock, as he said: “You could own JNJ and Merck with their incredible franchises. You know what? I’m actually particularly fond of JNJ right now. They’re spinning off their […]

Description: Market growth is propelled by improved diagnosis, genetic screening, and emerging therapies like statins, PCSK9 inhibitors, and gene therapies. Challenges include underdiagnosis and delayed treatment. Key players like Regeneron and Amgen are pioneering innovative solutions, enhancing the market landscape with precision medicine and genetic advancements.Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Familial Hypercholesterolemia Market - A Global and Regional Analysis: Focus on Country and Region

Description: The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%,

Description: NVIDIA, AT&T, and Amgen outperform peers as AI growth, 5G expansion, and strong drug sales drive investor optimism.

Description: Amgen recently announced that the FDA granted full approval to IMDELLTRA (tarlatamab-dlle) for adults with extensive stage small cell lung cancer (ES-SCLC) who have progressed after platinum-based chemotherapy, and the National Comprehensive Cancer Network updated its guidelines to list Tarlatamab as the only Category 1 preferred treatment option for this patient group. This development follows robust results from a global Phase 3 trial indicating IMDELLTRA extended median overall survival...

Description: NVIDIA's data center gains, AT&T's wireless momentum, and Amgen's product strength headline today's standout analyst reports.

Description: PASADENA, Calif., November 25, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2025 fiscal year ended September 30, 2025. The Company is hosting a conference call today, November 25, 2025, at 4:30 p.m. ET to discuss the results.

Description: The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.

Description: Amgen has underperformed the Nasdaq over the past year, but analysts are still fairly bullish about the biopharma stock's growth potential.

Description: Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the Company, in partnership with Amgen, received a 2025 Edison Patent Award from the Research & Development Council of New Jersey. The recognition was for their pioneering development of a biodegradable detergent that enables safer, more sustainable viral inactivation in biomanufacturing.

Description: When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than...

Description: Amgen (NASDAQ:AMGN) will present at Citi's 2025 Global Healthcare Conference at 1:45 p.m. ET on December 3, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

Description: Amgen (NASDAQ:AMGN) will present at the 8th annual Evercore ISI HealthCONx Conference at 10:00 a.m. ET on December 3, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

Description: Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the stocks Jim Cramer answered questions about. Answering a caller’s query about the stock, Cramer stated: “I should have been recommending Regeneron. That Len Schleifer pulled the rabbit out of a hat. It’s coming right back right now. By the way, I’ll give you a twofer, so is […]

Description: With many of the former leaders correcting considerably, medical stocks have offered a rare bright spot. Rising relative strength lines are making it clear that money is flowing to this area with ETFs like iShares Biotech ETF and SPDR Select Healthcare Select Sector SPDR Fund outperforming. Amgen is the top weight in IBB according to iShares data.

Description: For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date. It’s a challenge that Bristol Myers Squibb is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022. Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.

Description: While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Description: Amgen (NASDAQ: AMGN) announced today that the U.S. Food and Drug Administration (FDA) has granted full approval to IMDELLTRA® (tarlatamab-dlle) for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. The decision to convert IMDELLTRA's prior accelerated approval to a full approval is based on data from the global Phase 3 DeLLphi-304 study. Additionally, the National Comprehensive Cancer Network® (

Description: Investors must be patient and embrace diversification as they position themselves for a tech-stock rebound after this month’s slide. But they don‘t need an all-clear sign from Nvidia after the chip company’s earnings to wade back in. There are plenty of good opportunities in the market, even in some of the beaten-up tech and artificial intelligence names.

Description: FEATURE Healthcare stocks are recovering strongly as the year winds down. The is the best-performing of 11 major S&P sector funds over the past week, month, and three-month periods. The appeal of this group is its variety.

Description: The global renal anemia market is experiencing significant growth, driven by advancements in therapeutic options, increased diagnostic accuracy, and enhanced healthcare investments in the U.S., Europe, and emerging markets. The market is reshaped by the expansion of erythropoiesis-stimulating agents (ESAs), iron supplements, and novel oral hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs). Rising awareness about untreated renal anemia complications, such as fatigue, fuels the dem

Description: The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio

Description: We recently published 8 Stocks Jim Cramer Discussed & Mentioned An Important Quantum Computing Development. Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer discussed. Cramer has recently started to discuss pharmaceutical giant Amgen Inc. (NASDAQ:AMGN) more frequently. Most of his discussions surround the firm’s Repatha drug that aims to reduce cholesterol and prevent […]

Description: Eli Lilly might soon join them for a far different reason: the weight-loss bonanza. This year, Lilly has moved sharply ahead, securing Medicare access while widening its lead over Wegovy maker Novo Nordisk That is why investors shouldn’t assume the rally stops at a trillion. Lilly only began selling its weight-loss drug Zepbound in late 2023, and the Food and Drug Administration only declared an end to a supply shortage of obesity drugs last year.

Description: Amgen’s fair value target has seen a modest increase, now set at $318.51 compared to its previous level of $311.88. Recent analysis reflects both confidence in the company’s commercial strengths and innovation pipeline, along with caution about potential headwinds in a competitive market. Stay tuned to learn how investors can keep up with these evolving perspectives and make informed decisions about Amgen’s shifting narrative. Analyst Price Targets don't always capture the full story. Head...

Description: Amgen (AMGN) has caught some attention as its shares continued their upward trend in June, with the stock delivering a 13% gain over the past month. Investors are starting to re-evaluate the pharmaceutical giant's current valuation in light of these recent gains. See our latest analysis for Amgen. Amgen’s steady momentum isn’t just a one-month story. The stock’s 12.7% share price return over the past 30 days builds on a strong year-to-date climb of nearly 30%. Zooming out, its 1-year total...

Description: Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer mentioned in his latest comments. Cramer highlighted the company’s breakthrough medicine, as he remarked: “We had Amgen on the show the other day, announcing a breakthrough in Repatha, its every other week injection squelches cholesterol to a level where it helps prevent heart attacks. Why […]

Description: The pharmaceutical sector mainstay earned several positive mentions in the pundit sphere that day.

Description: Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently put under a microscope. Cramer showed quite a bullish sentiment toward the company’s stock, as he remarked: “If you want to venture beyond what we call the CPG, consumer packaged goods, world, I think you’d do very well with owning J&J or Amgen… Amgen’s […]

Description: Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently put under a microscope. Cramer said that “you’d do very well” owning the stock, as he stated: “If you want to venture beyond what we call the CPG, consumer packaged goods, world, I think you’d do very well with owning J&J or Amgen… […]

Description: Innovative drugmakers often make for solid dividend stocks. These two companies are great examples.

Description: Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Description: Thinking about whether Amgen is a smart buy at today's prices? You are not alone, especially if you are trying to figure out if the current stock price reflects true value or hype. Amgen's share price has surged recently, up 5.1% in the last week and 15.0% over the past month, with year-to-date returns sitting at an impressive 29.7%. Part of this momentum can be traced to news around major pipeline drug approvals and fresh partnerships that have caught investor attention. Ongoing discussions...

Description: Bank of America came up with 16 names that investors should consider buying. Renaissance Macro threw out a couple of sector ideas, too.

Description: We recently published 12 Fresh Stocks Jim Cramer Discussed Along With His Latest Thoughts On Quantum Computing. Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently discussed. Amgen Inc. (NASDAQ:AMGN) is a drug company that makes and sells medicines for a wide variety of ailments, such as arthritis and ulcers. Just like he […]

Description: The Dow is surging through the 48,000 threshold. The blue-chip index was up 344 points, or 0.7%, on Wednesday. It continued to beat the S&P 500 and Nasdaq Composite this week; the S&P was down 0.1%, while the Nasdaq was down 0.6%.

Description: Key Insights Institutions' substantial holdings in Amgen implies that they have significant influence over the...

Description: The company continued to bask in the glow of a very solid third quarter.

Description: U.S. stocks climbed Tuesday after Congress moved closer to ending the government shutdown, promising investors less commercial disruption and better insight into the state of the economy. A day after tech shares powered indexes higher, investors shifted money to other parts of the market, leading to sizable gains in the healthcare, energy and materials sectors. “It makes sense just to have some digestion of a really strong day yesterday,” said Matt Stucky, chief portfolio manager of equities at Northwestern Mutual Wealth Management.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied. This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied. This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer offered insights on. Cramer discussed the stock’s rally and the company’s cholesterol drug phase 3 trial. He stated: “In the last few weeks, the long-dormant healthcare sectors finally started to show a little life. It’s so inexpensive, it’s crazy. Take Amgen, the big biotech company […]

Description: Ellen Kullman, board director for Amgen, Carbon, and Goldman Sachs weighs in on the delicate balance between stakeholders and shareholders when creating company policies that impact employee engagement.

Description: Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Description: Turn’s Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar TherapeuticsLOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced it has been named as one of the “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine. “

Description: For most of Big Pharma, drug discounts have largely been about damage control. After months of tariff threats and talk of tougher pricing rules that weighed on their shares, several chief executives have made their way to the White House to announce drug-pricing deals in exchange for regulatory relief. For Eli Lilly’s   David Ricks and Novo Nordisk’s   Mike Doustdar, who paid their own visit to the White House last week, the calculus is different.

Description: Amgen’s third quarter results were well received by the market, reflecting robust volume-driven growth across its diversified portfolio. Management credited rising demand for key medicines—including Repatha, EVENITY, TEZSPIRE, and its rare disease and biosimilar portfolios—as major contributors to the company’s 12% year-over-year revenue increase. CEO Robert Bradway highlighted, “Volume growth reflects the strength of our portfolio and the value our medicines provide to patients and prescribers.

Description: GoodRx’s third quarter results were met with a moderate positive market response, as the company’s revenue modestly exceeded Wall Street expectations despite being flat year-over-year. Management highlighted a mix of strategic wins, such as expanded partnerships with pharmaceutical manufacturers and new pharmacy integrations, as key drivers. CEO Wendy Barnes cited the launch of direct-to-consumer pricing programs with major brands like Novo Nordisk and Amgen, as well as the rollout of the RxSmar

Description: The daily pill reduced LDL cholesterol by 56% in just six months, among patients whose LDL defy treatment with everyday statin drugs.

Description: Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.

Description: Amgen, Ciena, and Fair Isaac shine as Zacks' proven stock-ranking strategies continue to outperform amid market uncertainty.

Description: The lipid-reducing medicines, among the most widely prescribed drugs in the U.S., have been a mainstay of heart-disease prevention and treatment for decades. Now some patients have other cholesterol-busting medicines available as options—and even more alternatives are on the horizon. Certain patients already can take a twice-yearly injection, sold by Novartis as Leqvio, that uses an RNA-based technology, or a more frequent injection that targets a protein called PCSK9 that interferes with the body’s ability to clear the bad form of cholesterol.

Description: Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost 60%.

Description: Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and clinically meaningful reductions in major adverse cardiovascular events (MACE) in high-risk adults without a prior heart attack or stroke, when added to statins or other low-density lipoprotein cholesterol (LDL-C)–lowering treatments. Repatha is the first and only PCSK9 inhibitor to demonstrate a significant reduction of

Description: Amgen Inc. ( NASDAQ:AMGN ) investors will be delighted, with the company turning in some strong numbers with its latest...

Description: Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently shared thoughts on. Cramer said that the company needs to “broaden the portfolio,” as he remarked: “Look, I think Amgen needs to do something because they’ve gotta broaden the portfolio where they need to be able to tell a little bit better story about […]

Description: Quantinuum, the world leader in quantum computing, today announced the launch of Helios, the world's most accurate general-purpose commercial quantum computer, designed to accelerate quantum computing adoption by enterprises. With the highest fidelity† of any commercial system and a first-of-its-kind real-time control engine, Helios enables developers to program a quantum computer in much the same way they program heterogeneous classical computers. A new, modern Python-based programming language

Description: Amgen Inc. reported a robust third quarter 2025, with revenues rising to US$9.56 billion and net income increasing to US$3.22 billion, both surpassing prior-year figures and analyst expectations. Key highlights included a significant clinical milestone for Repatha, volume-driven sales growth across multiple products, and an upward revision of full-year financial guidance, underscoring the company's focus on innovation and expanding its therapeutic portfolio. We'll explore how Amgen's raised...

Description: The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. Co

Description: GoodRx Holdings Inc (GDRX) reports robust growth in manufacturer solutions but faces headwinds from prescription revenue decline and market uncertainties.

Description: Amgen (AMGN) delivered a sharp turnaround in profitability this year, with net profit margins rising to 19% from 10.1% previously and earnings forecast to grow 12.5% annually. While recent earnings growth soared by 111.5% after several years of decline, revenue is expected to grow at a more modest 1.9% per year, which is below the broader US market’s 10.4% pace. For investors, resilient profits, expanding margins, and valuation below fair value combine to create a constructive outlook as...

Description: Key Insights The projected fair value for Amgen is US$627 based on 2 Stage Free Cash Flow to Equity Current share price...

Description: Companies In The News Are: AMGN, EXEL, LITE, MCD.

Description: US equity indexes rose on Wednesday as leadership returning to communication services and consumer d

Description: Amgen stock popped Wednesday on a solid third-quarter beat as investors focus on what's next for the company's obesity treatment, MariTide.

Description: U.S. indexes finished higher Wednesday afternoon, with a rebound in AI stocks helping lift the Nasdaq composite 0.6%. Strong earnings and optimism from U.S. companies also spurred gains, with a rally in Amgen and Caterpillar shares lifting the Dow.

Description: Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index gaining 0.4% and th

Description: Its latest quarterly results were solid, thanks to strong sales of its top products.

Description: Royalty Pharma PLC (RPRX) reports robust growth in royalty receipts and raises full-year guidance, while navigating competitive challenges and strategic opportunities.

Description: Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index up 0.5% and the Health

Description: US equity indexes rose after midday Wednesday amid strong gains in communication services, a respite

Description: US benchmark equity indexes rose in midday trading on Wednesday as gains in communication services h

Description: The biotech heavyweight raises guidance again as fresh treatments offset pricing hits and patent risks mount.

Description: AMGN's Q3 earnings and revenues top estimates as key drugs drive double-digit growth. The company also raises its 2025 outlook.

Description: Amgen's (AMGN) new launches and pipeline progress are now under investor focus after the company top

Description: Pre-Market Futures: The futures are trading modestly higher as we reach the midpoint of the trading week, following a risk-off day on Tuesday that saw all major indices decline. The NASDAQ led the sell-off, closing over 2% lower, sparked by a dramatic drop in Palantir, despite the company posting results and guidance that beat expectations. ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: Amgen, Cloudflare, Shopify, Super Micro Computer, Wingstop and More

Description: Biotech company Amgen (NASDAQ:AMGN) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 12.4% year on year to $9.56 billion. The company’s full-year revenue guidance of $36.2 billion at the midpoint came in 1.5% above analysts’ estimates. Its non-GAAP profit of $5.64 per share was 12.4% above analysts’ consensus estimates.

Description: WALTHAM, Mass., November 05, 2025--Trinity, a leader in global life sciences commercialization, today announced the release of its 5th Annual TGaS Digital Marketing Competency Report, a three-part series benchmarking the digital marketing presence of more than 150 biopharma brands. The 2025 edition reveals a significant leap forward in the industry’s digital sophistication, with a 19% increase in Proficient brands and a surge of innovation in patient engagement strategies.

Description: The main US stock measures were tracking in the red in Wednesday's premarket activity as traders awa

Description: Soleno shares fell double digits amid questions about the growth trajectory of its Prader-Willi drug. Elsewhere, a cancer medicine at the center of a $1.9 billion buyout fell short in a key trial.

Description: Amgen Inc (AMGN) reports a 12% revenue increase and robust pipeline advancements, despite industry challenges and competitive pressures.

Description: Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Description: Amgen (AMGN) delivered earnings and revenue surprises of +12.80% and +6.87%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Investing.com -- Amgen beat Wall Street estimates for third-quarter profit and revenue on Tuesday, lifted by broad product strength and continued momentum in newer therapies such as Repatha and Tezspire.

Description: Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 12.4% year on year to $9.56 billion. The company’s full-year revenue guidance of $36.2 billion at the midpoint came in 1.5% above analysts’ estimates. Its non-GAAP profit of $5.64 per share was 12.5% above analysts’ consensus estimates.

Description: Amgen raised its outlook for the year after third-quarter profit jumped aided by sixteen products posting at least double-digit sales growth. The Thousand Oaks, Calif.-based biotechnology company on Tuesday reported a profit of $3.22 billion, or $5.93 a share, compared with a profit of $2.83 billion, or $5.22 a share, in the same quarter a year ago. Product sales rose 12%, with 14% volume growth offset by a 4% decline in net selling prices.

Description: Amgen crushed third-quarter expectations late Tuesday, thanks to big sales beats from blockbuster drugs Repatha and Prolia.

Description: On a per-share basis, the Thousand Oaks, California-based company said it had net income of $5.93. Earnings, adjusted for non-recurring gains, were $5.64 per share. The results surpassed Wall Street expectations.

Description: Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2025.

Description: US benchmark equity indexes were lower intraday as investors parsed the latest corporate earnings, w

Description: The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Description: US equity futures were trending lower on Tuesday as traders await the latest batch of corporate earn

Description: All eyes are on the government shutdown, which is nearing the longest on record. Meanwhile, investors will dig into earnings from McDonald’s, AMD and others. On Thursday, Tesla is due to publish the outcome of its shareholder vote on CEO Elon Musk’s pay package.

Description: US equity investors will focus on quarterly earnings this week, especially from companies that can b

Description: Following President Trump's return from Asia, eyes are on whether an end to the government shutdown is in sight. Meanwhile, investors will dig into earnings from McDonald’s, Palantir and a host of other companies.

Description: Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings this Tuesday after market close. Here’s what to look for.

Description: Recently, Royalty Pharma raised US$2 billion through senior unsecured notes and acquired royalty interests in Amgen's cancer drug IMDELLTRA, while also committing up to US$300 million for a royalty on Zenas BioPharma’s autoimmune drug candidate tied to clinical milestones. These moves reflect Royalty Pharma's focus on building a diversified, lower-risk revenue portfolio by investing in high-value, late-stage, and marketed drug assets. We'll explore how Royalty Pharma’s sizable funding...

Description: Markets look set to enter the fifth full week of a US government shutdown as investors parse Powell's comments, news of a trade deal between Washington and Beijing, and another mammoth week of earnings.

Description: Amgen (AMGN) received a key approval from the European Commission for Tezspire as an add-on therapy for severe chronic rhinosinusitis with nasal polyps, following strong Phase III results. The company is also preparing to share late-stage Repatha clinical data at an upcoming cardiology meeting, and its third quarter earnings report is just around the corner. See our latest analysis for Amgen. Amgen’s share price has climbed 15.1% year-to-date, supported by pipeline progress and steady product...

Description: Agilent Technologies (A) has announced Adam Elinoff will step in as Chief Financial Officer on November 17. Elinoff brings nearly two decades of leadership experience from Amgen, with a background in global finance and strategic transformation. See our latest analysis for Agilent Technologies. Agilent Technologies’ latest executive move comes during a strong run in the stock’s momentum. The share price has climbed 29% over the past 90 days, with a 5.6% gain over the past month, and currently...

Description: Market Domination Overtime host Josh Lipton previews several of the biggest stories to come throughout next week, including: — The nearing expiration of SNAP benefits funding (Supplemental Nutrition Assistance Program) as a federal judge orders the Trump administration to continue funding the program. — Earnings results from Berkshire Hathaway (BRK-A, BRK-B) this Saturday and quarterly results from companies like Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Qualcomm (QCOM), and McDonald's (MCD) throughout the rest of the week — The beginning of open enrollment for health insurance coverage. — Economic commentary from a handful of Federal Reserve officials. — Tesla's (TSLA) shareholder meeting, where investors will vote on CEO Elon Musk's $1 trillion executive pay package. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: The Standard & Poor's 500 index rose more than 0.7% this week, led by the information technology and

Description: Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the fourth quarter of 2025. The dividend will be paid on December 12, 2025, to all stockholders of record as of the close of business on November 21, 2025.

Description: The appointment fills a position made available when Bob McMahon resigned as CFO on July 31.

Description: Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Description: Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio, including late-breaking results from the Phase 3 VESALIUS-CV clinical trial of Repatha® (evolocumab), will be presented at the American Heart Association Scientific Sessions taking place November 7-10, 2025, in New Orleans, LA.

Description: Amgen stock has been underperforming the broader market over the past year, and analysts are adopting a cautiously bullish stance.

Description: Agilent Technologies appoints a new finance chief, Fiserv shakes up its leadership and railroad operator CSX names a new CFO.

Description: Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Description: Over the past year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a significant stake in the company which may have...

Description: Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2025 financial results on Tuesday, November 4, 2025, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.

Description: The Trump administration is proposing changes to Food and Drug Administration guidelines that would make it less expensive for drugmakers to develop biosimilar medicines, the copycat versions of off-patent biologic drugs. Under the new draft guidance, FDA would no longer require all biosimilar manufacturers to run clinical trials of their drugs as a condition of approval. Instead, the FDA says it will look at analytical studies that can show whether or not the biosimilar matches the branded drug it seeks to copy.

Description: Amgen's Q3 results are on deck, with growth from newer drugs offset by biosimilar competition and pricing pressures.

Description: Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Since the turn of the century, the Dogs of the Dow have significantly outperformed the overall market. These five are perfect plays for a slowing economy.

Description: Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: By Karen Roman Agilent Technologies, Inc. (NYSE: A) said it appointed Adam S. Elinoff as Chief Financial Officer starting on Nov. 17, who joins from having previously served Amgen as its vice president of finance and treasurer. Mr. Elinoff has over two decades of experience in corporate finance, investment relations, and business transformation, among others, […]

Description: SANTA CLARA, Calif., October 27, 2025--Agilent Technologies Inc. (NYSE: A) today announced the appointment of Adam S. Elinoff as chief financial officer, effective Nov. 17.

Description: The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

Description: If you're looking at Amgen and wondering whether it's time to buy, hold, or maybe even take profits, you're not alone. The stock has had its fair share of ups and downs lately, and investors are keeping a close eye on where it might go next. In the past month, we have seen Amgen’s price climb an impressive 6.9%, even after a modest dip of 2.4% last week. Year to date, the stock is up 12.5%, which suggests optimism is returning. Yet, the longer-term one-year return is still down 4.9%. When you...

Description: Zacks spotlights Amazon, Wells Fargo, Amgen, IDT and Village Super Market in its latest Analyst Blog, showcasing diverse growth drivers and risks.

Description: Its shares might not remain undervalued for that much longer.

Description: Amgen (AMGN) closed at $292.89 in the latest trading session, marking a -1.04% move from the prior day.

Description: Amazon's AI push, Wells Fargo's post-cap growth, and Amgen's new drug momentum headline Zacks' latest top analyst reports.

Description: The latest trading day saw Amgen (AMGN) settling at $295.98, representing a -1.71% change from its previous close.

Description: Although Amgen (currently trading at $299.86 per share) has gained 9.6% over the last six months, it has trailed the S&P 500’s 29.3% return during that period. This might have investors contemplating their next move.

Description: Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in adult and pediatric patients aged 12 years and older. TEZSPIRE is the first and only biologic approved for CRSwNP that targets thymic stromal lymphopoietin (TSLP).

Description: Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 results.